{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Antitumor+B", "query": { "intervention": "Antitumor B" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 88, "total_pages": 9, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Antitumor+B&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-08T05:38:43.637Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02906670", "title": "Sym013 (Pan-HER) in Patients With Advanced Epithelial Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Oncology" ], "interventions": [ { "name": "Sym013", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Symphogen A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2016-11-01", "completion_date": "2019-06", "has_results": true, "last_update_posted_date": "2020-08-28", "last_synced_at": "2026-09-08T05:38:43.637Z", "location_count": 3, "location_summary": "Nashville, Tennessee • San Antonio, Texas", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "San Antonio", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02906670" }, { "nct_id": "NCT02660034", "title": "The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "Tislelizumab", "type": "BIOLOGICAL" }, { "name": "Pamiparib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 229, "start_date": "2016-02-02", "completion_date": "2020-09-09", "has_results": true, "last_update_posted_date": "2021-12-06", "last_synced_at": "2026-09-08T05:38:43.637Z", "location_count": 12, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 8 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02660034" }, { "nct_id": "NCT02991911", "title": "A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Castration Resistant Prostate Cancer" ], "interventions": [ { "name": "MEDI3726 Post-Chemo", "type": "BIOLOGICAL" }, { "name": "MEDI3726 Pre-Chemo", "type": "BIOLOGICAL" }, { "name": "MEDI3726 & Enzalutamide Combo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "MALE", "summary": "18 Years to 100 Years · Male only" }, "enrollment_count": 33, "start_date": "2017-01-06", "completion_date": "2019-09-30", "has_results": false, "last_update_posted_date": "2020-01-18", "last_synced_at": "2026-09-08T05:38:43.637Z", "location_count": 3, "location_summary": "New Haven, Connecticut • Sarasota, Florida • Norfolk, Virginia", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Norfolk", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02991911" }, { "nct_id": "NCT05329103", "title": "A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "PEEL-224", "type": "DRUG" }, { "name": "FOLF+B", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Peel Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2022-07-11", "completion_date": "2026-10", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-09-08T05:38:43.637Z", "location_count": 8, "location_summary": "Scottsdale, Arizona • Palo Alto, California • Huntersville, North Carolina + 5 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT05329103" }, { "nct_id": "NCT06482905", "title": "Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "High-grade Glioma", "WHO Grade Ⅳ Glioma" ], "interventions": [ { "name": "Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Tcelltech Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 52, "start_date": "2024-09-04", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-03-24", "last_synced_at": "2026-09-08T05:38:43.637Z", "location_count": 3, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06482905" }, { "nct_id": "NCT00617409", "title": "To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Small Cell Lung Cancer" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Drug: Ad.p53-DC vaccines", "type": "BIOLOGICAL" }, { "name": "All -trans Retinoic Acid (ATRA)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 69, "start_date": "2007-10-02", "completion_date": "2019-01-31", "has_results": true, "last_update_posted_date": "2019-11-08", "last_synced_at": "2026-09-08T05:38:43.637Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00617409" }, { "nct_id": "NCT03530683", "title": "A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Multiple Myeloma", "Acute Myeloid Leukemia", "Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Maplirpacept (PF-07901801)", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Anti-CD20 Targeting agent", "type": "DRUG" }, { "name": "Isatuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 189, "start_date": "2018-05-14", "completion_date": "2024-07-18", "has_results": false, "last_update_posted_date": "2024-09-03", "last_synced_at": "2026-09-08T05:38:43.637Z", "location_count": 62, "location_summary": "Los Angeles, California • Pasadena, California • Denver, Colorado + 29 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03530683" }, { "nct_id": "NCT04931823", "title": "Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "CPO-100", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Conjupro Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2021-03-24", "completion_date": "2024-08-26", "has_results": false, "last_update_posted_date": "2026-04-03", "last_synced_at": "2026-09-08T05:38:43.637Z", "location_count": 8, "location_summary": "Los Angeles, California • New Haven, Connecticut • Las Vegas, Nevada + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "Lyndhurst", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04931823" }, { "nct_id": "NCT04649385", "title": "BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "BGB-15025", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 157, "start_date": "2021-03-04", "completion_date": "2026-05-15", "has_results": false, "last_update_posted_date": "2026-06-26", "last_synced_at": "2026-09-08T05:38:43.637Z", "location_count": 3, "location_summary": "New York, New York • Houston, Texas • San Antonio, Texas", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04649385" }, { "nct_id": "NCT04669587", "title": "ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study)", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Estrogen Receptor-Positive", "HER2-Negative", "Locally Advanced Breast Cancer", "Metastatic Breast Cancer" ], "interventions": [ { "name": "ZB716", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EnhancedBio USA Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 106, "start_date": "2021-07-26", "completion_date": "2024-01-31", "has_results": false, "last_update_posted_date": "2022-03-22", "last_synced_at": "2026-09-08T05:38:43.637Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04669587" } ] }